The US Federal Trade Commission announced Wednesday that pharmaceutical giant Novartis offered to divest its nicotine patch Habitrol to secure clearance for a joint venture.
Reports say Novartis offered the concessions to reduce competition concerns over its proposed partnership with UK-based GlaxoSmithKline. The agreement would see Novartis acquiring Glaxo’s oncology drugs portfolio, while Glaxo would take on Novartis’s non-flu vaccines operations.
But according to reports, the two conglomerates are among just three companies that sell nicotine patches to US retailers. Reports did not indicate whether the FTC will accept the concessions offered, however.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI